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Purpose: Studies documented that platelet activating factor (PAF) and the enzyme platelet activating factor
acetylhydrolase (PAFAH) play a very important role in the pathogenesis of neonatal necrotizing enterocolitis (NEC).
In this retrospective, case-controlled pilot study, the authors investigated the prevalence of single nucleotide
polymorphisms (Ile198Thr and Ala379Val) of the PAFAH gene.
Subjects and methods: We screened 570 blood samples from both Caucasian and African-American preterm
infants in the Northwest Louisiana population for the above mentioned PAFAH gene polymorphisms. Out of 570
infants, 36 had stage I or II NEC based on diagnostic coding, the International Classification of Diseases, 9th revision,
Clinical Modification, 2009 (ICD-9-CM). The remaining infants without an ICD-9-CM diagnosis of NEC were recruited
as control population. The DNA was isolated and restriction fragment length polymorphism microplate polymerase
chain reaction assay was performed.
Results: Variants of the PAFAH gene polymorphism (Ile198Thr and Ala379Val) frequencies were not significantly
different between the infants with NEC and the control group (P value of 0.26 by either multiple logistic regression
analysis or the Cochran-Mantel-Haenszel test).
Conclusions: This is the first study of its kind in exploring the relationship between NEC and single nucleotide
polymorphisms in the coding genes of the enzyme PAFAH. Our preliminary data demonstrated that adjusted for
the effect of race, PAFAH polymorphisms (Ile198Thr and Ala379Val) have no significant effect on NEC.
Keywords: Necrotizing enterocolitis; Neonates; Preterm; Single nucleotide polymorphisms; Platelet activating factor;
PAF; PAF acetylhydrolase; PAFAHBackground
Necrotizing enterocolitis (NEC) is the most common surgi-
cal gastrointestinal emergency in neonates with high
morbidity and mortality. The exact etiology of NEC is
still unknown and prematurity is considered as the most
important risk factor (Beeby & Jeffery 1992). More than
90% of the infants with NEC are born before 36 weeks
gestation (Henry & Moss 2009). Immaturity and ischemia* Correspondence: rdhanire@uthsc.edu
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reproduction in any medium, provided the origof the gut, infection and introduction of hyperosmolar feeds
are the key factors postulated in the development of NEC
(Henry & Moss 2009). Regardless of the underlying risk fac-
tors, the endogenous inflammatory mediators such as inter-
leukins, platelet activating factor (PAF) and nitric oxide
(NO) have been implicated in the final common pathogen-
esis of NEC (Edelson et al. 1999; Ewer 2002; Muguruma
et al. 1997; Caplan et al. 2005). PAF (1-O-alkyl-2-acetyl-
sn-glycero-3-phosphocholine) is a potent pro-inflammatory
mediator, involved in the signaling and activation of
proinflammatory cells such as platelets, neutrophils, and
macrophages (Prescott et al. 1990). PAF causes a variety ofThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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vascular permeability, bronchoconstriction and smooth
muscle contraction (Hsueh et al. 1994; Caplan et al. 1992;
Sun et al. 1994).
The proinflammatory effects of PAF are terminated by
the enzyme PAF acetylhydrolase (PAFAH). It exists in
two forms - intracellular and secretory. The secretory
form is found in breast milk and in other body fluids
(Moya et al. 1994). Studies in human infants with NEC
have shown increased luminal and systemic PAF and re-
duced expression of PAFAH (Caplan et al. 1990). In animal
models with NEC, increased levels of serum PAF and
decreased serum levels of the PAFAH have also been
clearly documented (Lu et al. 2010). The role of PAF and
PAFAH has been extensively documented in various disease
states involving inflammation (Tjoelker & Stafforini 2000).
Asthma and atopy are the prototypic diseases where
the role of PAF mediating inflammation been extensively
studied. Increased PAF and reduced PAFAH activity
have been proven in asthma patients (Tsukioka et al.
1996; Miwa et al. 1988). Ile198Thr (in exon 7, position
593;T > C) and Ala379Val (in exon 11, position 1136;T >C)
variants in PAFAH gene have been associated with an
increased risk for the development of atopy and asthma
in Caucasian population (Kruse et al. 2000). Even
though the role of PAF in NEC is well documented, no
prior study has been reported about the prevalence of
PAFAH variants in NEC infants and the role of poten-
tial pathogenesis. The rationale for the present study is
based on the research by Kruse et al. (2000). In neo-
nates, the polymorphisms of coding genes of various
enzymes involved in the inflammatory pathways can
influence various conditions such as respiratory distress
syndrome, bronchopulmonary dysplasia, intraventricular
hemorrhage and retinopathy of prematurity. For example, in
our previous studies, we have reported associations between
genotypes of the nitric oxide synthase gene and two
neonatal conditions namely intraventricular hemorrhage
and retinopathy of prematurity (Yanamandra et al. 2010;
Vannemreddy et al. 2009). In this prototype study, we
attempted to find the prevalence of the PAFAH variants
(Ile198Thr and Ala379Val) in Northwest Louisiana infants
both with and without NEC and any causal relationship
between these variants and the NEC.Table 1 Summary statistics on demographic and
gestational characteristics of the study subjects
NEC Ethnicity N Birth weight (gms) Gestational age (weeks)
Range Mean Range Mean
Yes C 20 1100-2837 2149 29.7 - 36.8 34.2
No C 192 720 - 2609 2278 27.6 - 36.8 33.9
Yes AA 16 810 - 1510 1224 24.7 - 32.1 29.1
No AA 342 540 - 2480 1965 23.4 - 36.8 32.8
NEC – necrotizing enterocolitis; C- Caucasian; AA – African-American.Materials and Methods
Subjects
Institutional review board (IRB) approval was obtained.
We screened peripheral EDTA blood samples from 570
preterm infants admitted to the neonatal intensive care
unit (NICU), Louisiana State University Health Sciences
Center, Shreveport, Louisiana for the presence of
Ile198Thr and Ala379Val polymorphisms.The diagnosis of NEC was based on diagnostic coding,
the International Classification of Diseases, 9th revision,
Clinical Modification, 2009; ICD-9-CM code for the
perinatal disorders of the digestive system – 777.5 is
NEC in newborn; 777.50 is NEC in newborn unspecified;
777.51 is stage I NEC; 777.52 is stage II NEC (NEC with
pneumatosis, without perforation) and 777.53 is stage III
(NEC with perforation or NEC with pneumatosis and
perforation) (The International Classification of Dis-
eases, 9th revision, Clinical Modification, 2009).
Only limited clinical information was available to us
such as ethnicity of the infants, gestational age and birth
weight. The important clinical information pertinent to
NEC such as feeding history, sepsis, presence of patent
ductus arteriosus, use of inotropes, administration of
indomethacin, radiological findings and surgical manage-
ment were not available for analysis.
Out of 570 infants, 36 infants (20 Caucasian infants
and 16 African-American infants) had either stage I or II
NEC. The number of infants with stage I and II were
equal in both ethnicities. In view of small numbers,
stages I and II were combined into one category. The 36
infants in the NEC population did not have the ICD-9-
CM diagnostic codes 777.5, 777.50 or 777.53. Also in
this sample of 570 infants, no infants died. The
remaining 534 infants (570–36) did not have any diag-
nostic coding for NEC, and they were recruited as the
control population. The control population included 192
Caucasian and 342 African-American infants. The
demographic and the gestational characteristics such as
birth weight and gestational age for the NEC and the
control groups were summarized in Table 1. In the
Caucasian group, the birth weight and the gestational
age in the NEC group and the control group were com-
parable (p value >0.05 by two sided z test). In the
African-American group, the NEC population was sig-
nificantly younger and more premature when compared
to the control group (p value < 0.05 by two sided z test).
Methods
DNA was isolated from patients and controls using
Qiagen blood mini DNA isolation kits. Microplate PCR
method was carried out for each polymorphism. The
Table 2 Study population classified based on three
variables (ethnicity, presence or absence of NEC and the
study genotypes)
PAFAH Genotypes
Ethnicity NEC (1) (2) (3) Total
Caucasian Yes 0 1 19 20
Caucasian No 7 36 149 192
African-American Yes 0 7 9 16
African-American No 22 123 197 342
Total 29 167 374 570
PAFAH Genotypes – (1) is 198 ThrThr + 379 ValVal (homozygous abnormal
genotype), (2) is 198 IleThr + 379AlaVal (heterozygous abnormal genotype) and
(3) is 198IleIle + 379AlaAla (homozygous normal genotype).
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by Kruse et al. (2000).
Ala379Val polymorphism
Briefly 10 microlitre (μl) of the PCR mix contained the
following components in the final concentration of
dH20 5.35 μl, 25 mM MgCl2 1.3 μl, 10× Applied
Biosystems buffer 1 μl, 3.75 pmoles of each of 4 dNTPs,
forward and reverse PAFAH primers 0.5 μl, Taq poly-
merase (gold, Perkin-Elmer) 0.5 units, and 1–2 ng of pa-
tient DNA. The primer sequences used were: GGG
AGA CAT AGA TTC AAC TG (forward) and CGT
TTT GTA AGA ATG CTA ATG A (reverse). The PCR
conditions used were : Initial denaturation for 10 min at
94°C, 35 cycles of the following program: 94°C for 45
seconds, 53°C for 90 seconds, 72°C for 90 seconds with
the final extension at 72°C for 10 minutes.
Enzyme digestion was carried out using nuclear en-
zyme buffer (0.5 μl), bovine serum albumin (0.01 μl) and
restriction endonuclease (Pst I). To 5 μl of the PCR
product, 1 μl of the enzyme mix was added and incu-
bated at 37°2C for 2 hours. The digested PCR fragments
were separated by electrophoresis on 3% agarose gel for
2 hours. Ethidium bromide staining was used to reveal the
fragments under an ultraviolet light transillumination.
Ile198Thr polymorphism
Assay parameters and conditions were similar as in the
Ala379Val except that the restriction enzyme was Pvu II
instead of Pst I, and the primer sequences were as fol-
lows: ATA AAT AAT TTT TGC TTG TAT (forward)
and AGA GCC AAG ACT TGT CAG CT (reverse).
Results
Distribution of PAFAH (Ile198Thr & Ala379Val) variants
In view of small sample size, both variants Ile198Thr
and Ala379Val were combined for analysis. In Table 2,
the study population was cross classified by three vari-
ables (ethnicity, presence or absence of NEC and the
study genotypes).
NEC group: Among the NEC group, the homozygous
abnormal genotype (198ThrThr + 379ValVal) was not
seen in any infants. Eight infants (1 Caucasian and 7
African-American infants) had heterozygous abnormal
genotype (198IleThr + 379AlaVal). The normal
homozygous (198IleIle + 379AlaAla) genotype was
found in 28 infants (19 Caucasian and 9 African-
American infants).
Control group: Among the control population of
healthy infants without NEC, homozygous abnormal
genotype (198ThrThr + 379ValVal) was seen in 29
infants (7 Caucasian + 22 African-American infants).
Heterozygous abnormal genotype (198IleThr +379AlaVal) was identified in 159 infants (36 Caucasian +
123 African-American infants). Normal homozygous
(198IleIle + 379AlaAla) genotype was found in 346 infants
(149 Caucasian + 197 African-American infants).Statistical analysis
Statistical analysis was performed using SAS Version 9.2
(SAS Institute Inc., Cary, NC, USA). A total of 570
infants were classified into three PAFAH genotypes-
198ThrThr + 379ValVal or homozygous abnormal geno-
type (represented as genotype 1), 198 IleThr + 379AlaVal
or heterozygous abnormal genotype (represented as
genotype 2) and 198IleIle + 379AlaAla or homozygous
normal genotype (represented as genotype 3). Table 2
shows the frequency of the genotypes stratified by ethni-
city (Caucasian or African-American) and disease status
(NEC present or absent). Given the relatively small sam-
ple size for genotype 1, which has zero infants with oc-
currence of NEC, it was combined with genotype 2 and
the combined group was considered abnormal genotype.
This combined cross classified table is illustrated in
Table 3.
Multiple logistic regression analysis was used to deter-
mine the effects of genotype and race on NEC occur-
rence adjusted for the effects of each other with the
following results (Table 4) Adjusted for the effect of
genotype, odds for NEC among Caucasian infants were
2.03 times the odds for NEC among African-American
infants in the study population. The adjusted odds ratio
(OR) was significant with p-value <0.05 and a 95% confi-
dence interval (CI), which did not contain 1 (value of
OR under the null hypothesis of no association between
race and NEC).
Adjusted for effect of race, genotype had no significant
effect on NEC; that is, adjusted for race, odds for NEC
among infants with abnormal genotype was similar to
those among infants with normal genotype. [Note: Al-
though the adjusted OR for genotype was not significant,
Table 3 Study population cross classified by three variables (ethnicity, presence or absence of NEC and the study
genotypes)
Ethnicity NEC Abnormal genotype Normal genotype Total
Caucasian Yes 1 19 20
Caucasian No 43 149 192
African-American Yes 7 9 16
African-American No 145 197 342
Total 196 374 570
In view of small numbers, the homozygous abnormal genotype (genotype 1 in Table 2) and heterozygous abnormal genotype (genotype 2 in Table 2) were
combined into one category (abnormal genotype).
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with abnormal genotype had smaller odds for NEC than
the infants with normal genotype].
Alternatively, since the focus of the study was on the
role of polymorphisms in the etiology of NEC, the 3-way
cross classified table was analyzed with the 2 races as
strata in determining the association between PAFAH
genotype and NEC using the Cochran-Mantel-Haenszel
(CMH) test.
The CMH statistic, its 95% CI and its p-value were calcu-
lated as CMH statistic = 1.65, 95% CI = (0.71 to 3.84),
p-value = 0.26. The CMH statistic was not significant as its
95% CI contained 1 and its p-value > 0.05. Thus, when the
infants were stratified by race (Caucasian or African-
American) there was no association between genotype and
NEC. The p-value for the CMH statistic (p = 0.26) was the
same as the p-value for the adjusted OR for abnormal vs.
normal genotype (p = 0.26) using multiple logistic regres-
sion analysis. Also, the CMH did not test for effect of race;
rather it was used to stratify the infants.
Discussion
Necrotizing enterocolitis (NEC) remains one of the lead-
ing causes of morbidity and mortality in neonatal inten-
sive care units, with an incidence of 10% among very
low birth weight infants (<1500 grams) (Uauy et al.
1991) and a mortality of approximately 26% (Hack et al.
1991). The lower the gestational age and birth weight,
higher is the risk of developing NEC. Despite improve-
ments in overall neonatal survival, this mortality rate has
not changed significantly over the last three decades
(Henry & Moss 2009; Ewer 2002). In addition to the
mortality, NEC is associated with high morbidityTable 4 Results of multiple logistic regression analysis on
the study population for the occurrence of NEC
Factor Odds ratio (OR) 95% CI for OR p-value
Race (C vs. AA) 2.03 1.01 – 4.07 0.046*
Genotype
Abnormal vs. Normal 0.62 0.27 – 1.42 0.26NS
C- Caucasian; AA – African-American. *Significant at 5% level (0.01 < p-value
< 0.05) NS Not significant at 5% level (p-value > 0.05).resulting from multiple surgeries, need for parenteral
nutrition, cholestatic liver disease and development of
short gut syndrome.
Although several predisposing factors such as prema-
turity, bacterial infection, enteral feeding and gut ische-
mia have been identified, the exact pathogenesis of NEC
remains unknown (Beeby & Jeffery 1992). Regardless of
the initial triggering factor, the final pathology is similar
which strengthens the possibility of the role of inflam-
matory mediators such as platelet activating factor (PAF)
(Ewer 2002; Muguruma et al. 1997; Caplan et al. 2005).
PAF is an endogenous phospholipid with potent
proinflammatory actions. It is synthesized from the
plasma membrane precursors by cells such as intestinal
cells and neutrophils. The half-life is very short and it is
degraded by the enzyme PAF acetylhydrolase (PAFAH).
PAFAH can be therefore be considered as the functional
antagonist of PAF. The PAF receptor is a G protein-
coupled seven transmembrane domain receptor family
(GPCR). PAF combines with its receptor which is
present on most cells resulting in activation of the in-
flammatory cascade (Caplan et al. 2005; Prescott et al.
1990). The exact mechanism of pathogenesis of PAF in
NEC is not known, but exposure to a high local concen-
tration of PAF results in increased mucosal permeability,
apoptosis, activation of inflammatory cascade and finally
bowel necrosis (Frost et al. 2008).
Numerous clinical and experimental studies have sub-
stantially strengthened our understanding of the role of
PAF and PAFAH in the pathogenesis of NEC. The
PAFAH activity is generally lower in newborns com-
pared to adults, which enhances the susceptibility of
neonates to the NEC (Caplan et al. 1990). NEC induced
by intravenous administration of PAF has been docu-
mented in neonatal experimental piglet models (Ewer
et al. 2004) and also in rats (Gonzalez-Crussi & Hsueh
1983). Both in human and animal subjects, it has been
proven that in NEC, the local as well as systemic concen-
trations of PAF were significantly high with concurrent
decreased expression of PAFAH (Caplan et al. 1990; Lu
et al. 2010). Increased concentration of stool PAF in NEC
has also been documented (Amer et al. 2004). In contrast,
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found in the neonatal population particularly in infants
with NEC (Caplan et al. 1990). Additionally, enteral ad-
ministration of recombinant PAFAH or PAF receptor an-
tagonist to neonatal rats resulted in a significant decrease
in NEC (Caplan et al. 1997; 1997) strengthening the con-
cept of functional antagonism of PAFAH in the NEC med-
icated by PAF.
The human PAF acetylhydrolase gene is located in
chromosome 6p12.p21.1. (Stafforini et al. 1996). Re-
duced PAFAH has been documented in many disease
states where PAF plays a role in mediating the inflam-
mation such as in asthma (Kruse et al. 2000), sepsis
(Graham et al. 1994), stroke (Satoh 2008; Hiramoto
et al. 1997), multiple organ failure (Partrick et al. 1997)
and myocardial infarction (Yamada et al. 1998). A differ-
ence in PAFAH activity between individuals/ethnicities
has been extensively studied and genetic variations in
the candidate genes has been proposed as the etiology
for this difference in activity (Tjoelker & Stafforini 2000;
Stafforini et al. 1996). The single nucleotide polymor-
phisms (SNPs) commonly described in the human
PAFAH gene were Arg92His (exon 4), Ile198Thr (exon 7),
Val279Phe (exon 9), Gln281Arg (exon 9) and Ala379Val
(exon 11) (Li et al. 2009). The influence of these PAFAH
polymorphisms is well studied in many disease states
where PAF plays a significant role in the pathogenesis.
The role of SNPs in the pathogenesis of diseases is vari-
able in different ethnicities and controversial (Kruse et al.
2000; Li et al. 2009). For example, in the Japanese popula-
tion, two loss of function mutations on PAFAH gene
have been described in asthmatic children and similar
mutations were not seen in the Caucasian population
with asthma (Kruse et al. 2000; Stafforini et al. 1999).
The two PAFAH variants (Ile198Thr and Ala379Val)
were also studied in conditions such as asthma (Kruse
et al. 2000), aging (Campo et al. 2008), acute respiratory
distress syndrome (Li et al. 2009) and in schizophrenia
(Bell et al. 1997; Ohtsuki et al. 2002). Even though the
role of PAF in NEC is well known, similar SNP studies
in the PAFAH gene have not been reported in the litera-
ture. We selected the two PAFAH variants (Ile198Thr
and Ala379Val) based on the study by Kruse et al.
(2000). Kruse et al. (2000) demonstrated that in Cauca-
sian population, Thr198 and Val379, the two common
variants of the PAFAH gene were associated with lower
substrate affinities (higher Km) of PAFAH. They also
demonstrated that decreased affinity of PAFAH for PAF
results in reduced catalytic activity of PAFAH, which is
believed to further prolong the activity of PAF and
increase the risk of development of asthma and atopy.
We applied this rationale to our study and attempted to
find out the relationship between the two PAFAH variants
and NEC.In our study population, adjusted for the effect of race,
genotypic variants had no significant effect on NEC; that
is, adjusted for race, odds for NEC among infants with
an abnormal genotype was similar to those among in-
fants with a normal genotype. Because of the contro-
versial relationship of variant genotypes to the PAFAH
enzyme levels in different ethnicities (Kruse et al. 2000;
Stafforini et al. 1999) and our study being the first study
of its kind in the literature, the exact significance of our
observations is unknown at present.
There are several limitations in this study that warrant
discussion. First, the sample size was small. The concur-
rent measurements of PAF and PAFAH activity would
be more meaningful. As our study was retrospective,
concurrent measurements of PAF and PAFAH levels
were not feasible. Another limitation is that the defin-
ition and the inclusion criteria for NEC was strictly
based on diagnostic coding, the International Classifica-
tion of Diseases, 9th revision, Clinical Modification,
2009; ICD-9-CM. Even though very desirable, pertinent
clinical information such as feeding history, sepsis,
presence of patent ductus arteriosus, use of inotropes,
indomethacin, etc. which play a vital role in the etio-
pathogenesis of NEC were not taken for analysis due to
unavailability. Our study sample did not have advanced
stages of NEC such as stage 3 NEC (NEC with intestinal
perforation or NEC with pneumatosis with perforation)
or infants who died from NEC which is also a limitation.
Despite the limitations, our study is a prototype pilot
study in providing the prevalence of PAFAH gene poly-
morphisms in the Northwest Louisiana population. Also
we attempted to find a relationship between PAFAH var-
iants and NEC. A Medline search using the terms “nec-
rotizing enterocolitis” and “platelet activating factor
acetylhydrolase” revealed 20 articles. To the best of our
knowledge, a detailed review of these articles did not re-
veal any previous study showing the role of PAFAH
polymorphisms in the pathogenesis of NEC. Based on
our results, we conclude that PAFAH genotype variants
(Ile198Thr and Ala379Val) have no significant effect on
NEC. A prospective study involving a larger population
with concurrent measurements of PAF and PAFAH
along with detailed clinical information is recommended
to confirm or refute our initial findings.Competing interests
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